ZME Science
No Result
View All Result
ZME Science
No Result
View All Result
ZME Science

Home → Science

Ebola may now be curable, clinical trial in Congo finds

"Now we can say that 90 percent can come out of treatment cured,” one scientist said in a statement. 

Tibi PuiubyTibi Puiu
August 12, 2019
in Health, Science
A A
Share on FacebookShare on TwitterSubmit to Reddit
Credit: NIAID, Flickr.

The first-ever multi-drug randomised trial for Ebola has proven extremely successful. Researchers treating patients in the Democratic Republic of Congo (DRC) have identified two monoclonal antibodies that block the Ebola virus and radically lower mortality. The new findings suggest that Ebola is no longer an incurable disease.

“Now we can say that 90 percent can come out of treatment cured,” one scientist said in a statement. 

Ebola is a devastating disease, characterized by a painful hemorrhagic fever, which interferes with the endothelial cells lining the interior surface of blood vessels and with coagulation. As the blood vessel walls become damaged and destroyed, the platelets are unable to coagulate, and patients succumb to hypovolemic shock. 

When the Ebola virus infects a human host, it it can kill up to 90% of the time, depending on available treatment.  The 2014–2016 outbreak in West Africa was the largest and most complex Ebola outbreak since the virus was first discovered in 1976. There were more cases and deaths in this outbreak than all others combined. 

To contain the epidemic, doctors in Sierra Leone, Libera, and Guinea have been using biopharmaceutical drugs like ZMapp and Remdesivir. However, these drugs have now been droppped in favor of two monoclonal antibodies, known as REGN-EB3 and mAb-114, which a recent clinical trial showed to be far more effective. 

The DRC trial, which started in November, found that a monoclonal antibody drug made by Regeneron has a mortality rate of only 29% while another monoclonal antibody made by Ridgeback Biotherapetics had a mortality rate of 34%. Meanwhile, Zmapp and Remdesivir had a mortality rate of 49% and 53% respectively. 

The odds of suriviving Ebola, however, are much higher if a patient arrives early at a clinic. The trial found that the death rate for those seeking treatment soon after they became sick was only 11% with the Ridgeback antibody and just 6% with Regeneron’s drug. 

According to the World Health Organization, people who fall ill with Ebola wait on average four days before they seek treatment. Many are reluctant to call for help because the chances of survival in clinics has been very low — until recently, up to 70% of those infected with Ebola in the DRC have died. 

RelatedPosts

Congo’s Ebola outbreak is likely over, official confirmation to come in 21 days
The EU approves first-ever human Ebola vaccine for public use
Drug saves monkeys from Marburg virus – a close relative of Ebola
Ebola countries record first week with no new cases

This may finally change with this groundbreaking trial now that Ebola is preventable and treatable. 

Tags: Ebola

ShareTweetShare
Tibi Puiu

Tibi Puiu

Related Posts

Health

Uganda is struggling to contain outbreak of untreatable Ebola strain. Two vaccine candidates to be deployed

byAlexandru Micu
3 years ago
Health

FDA approves first Ebola treatment

byMelvin Sanicas
5 years ago
Diseases

New Ebola outbreak hits Congo, with five deaths and growing concerns

byFermin Koop
5 years ago
Science

The EU approves first-ever human Ebola vaccine for public use

byAlexandru Micu
6 years ago

Recent news

Scientists Just Proved Ancient Humans Were in North America 10,000 Years Earlier Than We Thought

June 30, 2025

What’s Seasonal Body Image Dissatisfaction and How Not to Fall into Its Trap

June 28, 2025

Why a 20-Minute Nap Could Be Key to Unlocking ‘Eureka!’ Moments Like Salvador Dalí

June 28, 2025
  • About
  • Advertise
  • Editorial Policy
  • Privacy Policy and Terms of Use
  • How we review products
  • Contact

© 2007-2025 ZME Science - Not exactly rocket science. All Rights Reserved.

No Result
View All Result
  • Science News
  • Environment
  • Health
  • Space
  • Future
  • Features
    • Natural Sciences
    • Physics
      • Matter and Energy
      • Quantum Mechanics
      • Thermodynamics
    • Chemistry
      • Periodic Table
      • Applied Chemistry
      • Materials
      • Physical Chemistry
    • Biology
      • Anatomy
      • Biochemistry
      • Ecology
      • Genetics
      • Microbiology
      • Plants and Fungi
    • Geology and Paleontology
      • Planet Earth
      • Earth Dynamics
      • Rocks and Minerals
      • Volcanoes
      • Dinosaurs
      • Fossils
    • Animals
      • Mammals
      • Birds
      • Fish
      • Amphibians
      • Reptiles
      • Invertebrates
      • Pets
      • Conservation
      • Animal facts
    • Climate and Weather
      • Climate change
      • Weather and atmosphere
    • Health
      • Drugs
      • Diseases and Conditions
      • Human Body
      • Mind and Brain
      • Food and Nutrition
      • Wellness
    • History and Humanities
      • Anthropology
      • Archaeology
      • History
      • Economics
      • People
      • Sociology
    • Space & Astronomy
      • The Solar System
      • Sun
      • The Moon
      • Planets
      • Asteroids, meteors & comets
      • Astronomy
      • Astrophysics
      • Cosmology
      • Exoplanets & Alien Life
      • Spaceflight and Exploration
    • Technology
      • Computer Science & IT
      • Engineering
      • Inventions
      • Sustainability
      • Renewable Energy
      • Green Living
    • Culture
    • Resources
  • Videos
  • Reviews
  • About Us
    • About
    • The Team
    • Advertise
    • Contribute
    • Editorial policy
    • Privacy Policy
    • Contact

© 2007-2025 ZME Science - Not exactly rocket science. All Rights Reserved.